Acquisition Opportunity IBA Dosimetry recently expanded its US footprint by acquiring Radcal Corporation, an X-ray imaging specialist. This move broadens capabilities and customer reach in radiography QA, signaling potential cross-sell of calibration, QA software, and imaging markers to Radcal’s established installed base.

Integrated QA Platform The company has launched the myQA iON integrated QA platform and enhanced myQA Machines software, underscoring a shift toward comprehensive QA ecosystems. This creates opportunities to upsell modular QA modules, remote monitoring, and data analytics services to existing customers seeking end-to-end radiation therapy QA solutions.

Global Presence Headquartered in Germany with subsidiaries in the US and China, IBA Dosimetry presents a multinational footprint. This suggests potential for region-specific product bundles, localized support contracts, and multi-country deployments for hospital networks expanding to new markets.

Market Positioning Positioned as a leading dosimetry solution provider with a focus on precision and safety in radiotherapy and radiodiagnostics, there is opportunity to leverage their brand to pursue larger hospital systems, academic centers, and radiation oncology networks seeking trusted QA partners and scalable calibration solutions.

Financial Scale With a revenue range of 1M to 10M and a mid-sized employee base, target opportunities include mid-tier hospitals and regional cancer centers that require cost-effective, high-quality QA solutions and service bundles, enabling scalable growth without the complexity of enterprise-level vendors.